{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:09:15Z","timestamp":1791173355749,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T00:00:00Z","timestamp":1360195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001659","name":"The Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["FOR 1202, TP1 and TP3"],"award-info":[{"award-number":["FOR 1202, TP1 and TP3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"The Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["LO 1556\/1-2"],"award-info":[{"award-number":["LO 1556\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Swiss National Science Foundation","award":["31003A-138484"],"award-info":[{"award-number":["31003A-138484"]}]},{"name":"The french ANRS"},{"name":"NIH","award":["U19AI066328"],"award-info":[{"award-number":["U19AI066328"]}]},{"name":"NIH","award":["R01AT006842"],"award-info":[{"award-number":["R01AT006842"]}]},{"name":"NIH","award":["R56AI091840"],"award-info":[{"award-number":["R56AI091840"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Intravenous silibinin (SIL) is an approved therapeutic that has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C virus (HCV) infection in some patients even in monotherapy. Previous studies suggested multiple antiviral mechanisms of SIL; however, the dominant mode of action has not been determined. We first analyzed the impact of SIL on replication of subgenomic replicons from different HCV genotypes<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>and found a strong inhibition of RNA replication for genotype 1a and genotype 1b. In contrast, RNA replication and infection of genotype 2a were minimally affected by SIL. To identify the viral target of SIL we analyzed resistance to SIL<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>and<\/jats:bold>\n                                 <jats:bold>\n                                    in vivo\n                                 <\/jats:bold>. <jats:bold>Selection for drug resistance in cell culture identified a mutation in HCV nonstructural protein (NS) 4B conferring partial resistance to SIL. This was corroborated by sequence analyses of HCV from a liver transplant recipient experiencing viral breakthrough under SIL monotherapy. Again, we identified distinct mutations affecting highly conserved amino acid residues within NS4B, which mediated phenotypic SIL resistance also<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>. <jats:bold>Analyses of chimeric viral genomes suggest that SIL might target an interaction between NS4B and NS3\/4A. Ultrastructural studies revealed changes in the morphology of viral membrane alterations upon SIL treatment of a susceptible genotype 1b isolate, but not of a resistant NS4B mutant or genotype 2a, indicating that SIL might interfere with the formation of HCV replication sites.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Mutations conferring partial resistance to SIL treatment<\/jats:bold>\n                                 <jats:bold>\n                                    in vivo\n                                 <\/jats:bold>\n                                 <jats:bold>and in cell culture argue for a mechanism involving NS4B. This novel mode of action renders SIL an attractive candidate for combination therapies with other directly acting antiviral drugs, particularly in difficult-to-treat patient cohorts. (Hepatology 2013)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26260","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T20:26:47Z","timestamp":1358281607000},"page":"953-963","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":51,"title":["Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B"],"prefix":"10.1097","volume":"57","author":[{"given":"Katharina","family":"Esser-Nobis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Romero-Brey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom M.","family":"Ganten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Gouttenoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Harak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Moradpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bartenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Polyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Stremmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Penin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Eisenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-16-20241201","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection.","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J Hepatol"},{"key":"R2-16-20241201","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0091270009347475","article-title":"Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.","volume":"50","author":"Hawke","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R3-16-20241201","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jhep.2010.09.009","article-title":"Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.","volume":"54","author":"Beinhardt","year":"2011","journal-title":"J Hepatol"},{"key":"R4-16-20241201","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jhep.2010.02.002","article-title":"Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin monotherapy.","volume":"52","author":"Neumann","year":"2010","journal-title":"J Hepatol"},{"key":"R5-16-20241201","first-page":"1","article-title":"Treatment of hepatitis Cvirusreinfection after liver transplant with silibinin in nonresponders to pegylated interferonbased therapy.","volume":"9","author":"Eurich","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"R6-16-20241201","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3851\/IMP1942","article-title":"Intravenous silibinin as rescue treatment for ontreatment nonresponders to pegylated interferonribavirin combination therapy.","volume":"16","author":"Rutter","year":"2011","journal-title":"Antivir Ther"},{"key":"R7-16-20241201","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcv.2010.07.006","article-title":"Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIVHCV coinfected patient.","volume":"49","author":"Payer","year":"2010","journal-title":"J Clin Virol"},{"key":"R8-16-20241201","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2009.02.087","article-title":"Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.","volume":"137","author":"Biermer","year":"2009","journal-title":"Gastroenterology"},{"key":"R9-16-20241201","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2893.2011.01572.x","article-title":"Highdose silibinin rescue treatment for HCVinfected patients showing suboptimal virologic response to standard combination therapy.","volume":"19","author":"Biermer","year":"2012","journal-title":"J Viral Hepat"},{"key":"R10-16-20241201","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","article-title":"Silibinin and related compounds are direct inhibitors of hepatitis C virus RNAdependent RNA polymerase.","volume":"138","author":"AhmedBelkacem","year":"2010","journal-title":"Gastroenterology"},{"key":"R11-16-20241201","doi-asserted-by":"crossref","first-page":"e16464","DOI":"10.1371\/journal.pone.0016464","article-title":"Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.","volume":"6","author":"Wagoner","year":"2011","journal-title":"PLoS One"},{"key":"R12-16-20241201","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1128\/JVI.00032-07","article-title":"Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras.","volume":"81","author":"Binder","year":"2007","journal-title":"J Virol"},{"key":"R13-16-20241201","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chom.2010.12.002","article-title":"Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.","volume":"9","author":"Reiss","year":"2011","journal-title":"Cell Host Microbe"},{"key":"R14-16-20241201","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/rmv.640","article-title":"Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory.","volume":"20","author":"Gouttenoire","year":"2010","journal-title":"Rev Med Virol"},{"key":"R15-16-20241201","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/j.gastro.2008.07.072","article-title":"Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferonribavirin therapy.","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"R16-16-20241201","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1128\/JVI.78.15.7904-7915.2004","article-title":"Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells.","volume":"78","author":"Yi","year":"2004","journal-title":"J Virol"},{"key":"R17-16-20241201","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"R18-16-20241201","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1128\/JVI.77.9.5487-5492.2003","article-title":"Identification of the hepatitis C virus RNA replication complex in huh7 cells harboring subgenomic replicons.","volume":"77","author":"Gosert","year":"2003","journal-title":"J Virol"},{"key":"R19-16-20241201","doi-asserted-by":"crossref","first-page":"11378","DOI":"10.1128\/JVI.01122-09","article-title":"An amphipathic alphahelix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association.","volume":"83","author":"Gouttenoire","year":"2009","journal-title":"J Virol"},{"key":"R20-16-20241201","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1128\/JVI.00502-11","article-title":"NS4B selfinteraction through conserved Cterminal elements is required for the establishment of functional hepatitis C virus replication complexes.","volume":"85","author":"Paul","year":"2011","journal-title":"J Virol"},{"key":"R21-16-20241201","doi-asserted-by":"crossref","first-page":"12529","DOI":"10.1128\/JVI.01798-10","article-title":"Amphipathic alphahelix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B.","volume":"84","author":"Gouttenoire","year":"2010","journal-title":"J Virol"},{"key":"R22-16-20241201","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.","volume":"76","author":"Egger","year":"2002","journal-title":"J Virol"},{"key":"R23-16-20241201","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1073\/pnas.0914009107","article-title":"Identification of hepatoprotective flavonolignans from silymarin.","volume":"107","author":"Polyak","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-16-20241201","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1128\/JVI.00875-08","article-title":"A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication.","volume":"82","author":"Paredes","year":"2008","journal-title":"J Virol"},{"key":"R25-16-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1745-7254.2007.00487.x","article-title":"Influence of silybin on biophysical properties of phospholipid bilayers.","volume":"28","author":"Wesolowska","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"R26-16-20241201","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3390\/v2112481","article-title":"The future of HCV therapy: NS4B as an antiviral target.","volume":"2","author":"DvorySobol","year":"2010","journal-title":"Viruses"},{"key":"R29-16-20241201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5812\/hepatmon.6135","article-title":"Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection.","volume":"12","author":"Aghemo","year":"2012","journal-title":"Hepat Mon"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26260","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201303000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:07:33Z","timestamp":1733062053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201303000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26260","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}